Open AccessPeripherally acting μ-opioid receptor antagonists for treatment of opioid-induced constipation in children
Author(s) -
Chris Novak,
Amanda Hogg,
Kyle Sue,
Dawn Davies
Publication year - 2020
Publication title -
paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.55
H-Index - 43
eISSN - 1918-1485
pISSN - 1205-7088
DOI - 10.1093/pch/pxz165
Subject(s) - medicine , constipation , opioid , adverse effect , enteral administration , palliative care , prospective cohort study , anesthesia , intensive care medicine , parenteral nutrition , nursing , receptor
Opioid-induced constipation (OIC) is a common and important problem in paediatric palliative care, critical care, and postoperative settings. Treatment for OIC is often ineffective and limited by enteral intake. A new class of drugs called peripherally acting mu-opioid receptor antagonists (PAMORAs) have been shown to be effective treatments of OIC in adults, including the agents methylnaltrexone and naloxegol. Data in children are limited to several small case reports, mostly in the palliative care setting. The goal of this study was to evaluate the effectiveness and safety of methylnaltrexone and naloxegol in hospitalized children, including those with critical illness.